RYTMRhythm Pharmaceuticals, Inc.

$90.85-5.4% 1Y

Is it safe?

Mixed

Forensics clean, with a caveat: a safe balance sheet and clean books, but big price swings.

3 good, 1 to watch, 2 neutral
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality6 / 9

Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Insider conviction-$28.8M

Insiders were net sellers (-$28.8M, 90 days to Oct 8, 2026), selling is often routine.

Credit gradeAAderived · Jun 30, 2026

Net cash and profitable. A rule of thumb on leverage, not a credit rating.

Drawdown risk53% volderived · Oct 9, 2026

Large price swings, high volatility. Worst drawdown -92% · now 23% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybehind 69% of the market
Max drawdownbottom 9% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can RYTM take a bad year?

Rhythm Pharmaceuticals, Inc. holds $225M more cash than debt, so a bad year is a question about profits, not about lenders.

$225M

Net cash

Net debt / EBITDA
net cash

Net debt / EBITDA · no net borrowings to measure against earnings

Altman Z-score
9.10

Altman Z-score · safe zone, above 3

Interest cover
none

Interest cover · no operating profit to pay the interest bill from

Details›
Total debtQ2 2026
$106M
Cash and short-term investments
$331M
Net cash
$225M
Operating profit, trailing twelve months
−$201M
Debt / equity
1.03×
Annualised volatilitytwo years of daily moves
53%
Worst drawdown on file
−92%
Below its 52-week high
23%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.